Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Zymeworks (Canada) a preclinical-stage biopharma focused on protein-based therapeutics for oncology and inflammatory disease, closed a $8.1M Series D financing. Participants include CTI Life Sciences Fund and Advanced Biotechnologies Venture Fund. Thanx for your patience as we catch-up.

Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $10.5M Series B financing. Participants were not identified.

F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include SR One, MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

Arsanis (Austria) a development stage biopharma focused on fully human monoclonal antibodies against severe infectious diseases, closed a $10M A financing. Participants include OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences.

Symphogen (Denmark) a clinical-stage developer of recombinant polyclonal antibodies for the treatment of cancer and infectious and autoimmune diseases, closed a $135.4M Series F financing. Participants include Essex Woodlands Health Ventures, Novo, and Pensionskassernes Administration.

Covagen (Switzerland) a development-stage biopharmaceutical company focused on a protein scaffold platform (Fynomer) for therapeutic use, closed a $6.5M Series A financing. Participants include Seroba Kernel Life Sciences, Edmond de Rothschild Investment Partners, MP Healthcare Venture Management, Novartis Venture Fund and Ventech.

NovImmune (Switzerland) a clinical-stage biopharmaceutical company focused on monoclonal antibodies for the treatment of inflammation and immune related disorders, closed a $20.8M Series B financing. Participants include BZ Bank Aktiengesellschaft.

Delenex Therapeutics (Switzerland) a clinical-stage biopharmacetucial company developing therapeutic antibody fragments targeting CNS and dermatological disease, closed a $14M Series A financing. Participants include SV Life Sciences, HBM BioCapital, BioMed Partners and VI Partners.

Femta Pharmaceuticals (San Diego, CA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for the treatment of inflammation and autoimmune disease, closed a $2.2M Series A financing. Participants include Latterell Venture Partners.

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $4.5M Series A financing. Participants were not identified.

CytomX Therapeutics (San Francisco, CA) a development-stage biopharmaceutical company focused on protease-activated antibody therapeutics, closed a $30M Series B financing. Participants include Third Rock Ventures and Roche Venture Fund.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...